Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Gene dosage of the apolipoprotein E (APOE) epsilon 4 allele is a major risk factor for familial Alzheimer disease (AD) of late onset (after age 60). Here we studied a large series of 115 AD case subjects and 243 controls as well as 150 affected and 197 unaffected members of 66 AD families. Our data demonstrate a protective effect of the epsilon 2 allele, in addition to the dose effect of the epsilon 4 allele in sporadic AD. Although a substantial proportion (65%) of AD is attributable to the presence of epsilon 4 alleles, risk of AD is lowest in subjects with the epsilon 2/epsilon 3 genotype, with an additional 23% of AD attributable to the absence of an epsilon 2 allele. The opposite actions of the epsilon 2 and epsilon 4 alleles further support the direct involvement of APOE in the pathogenesis of AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“APOE, the major susceptibility gene for late-onset AD, has three common alleles (APOE2, 3, and 4).”
From Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report (2019) · cites this paper as [10]
In the citing paper
“Compared to the most common APOE3/3 genotype, which is considered neutral with regard to AD risk, APOE2 is associated with a lower AD risk and older age at dementia onset, and each additional copy of APOE4 is associated with a higher risk and younger age at onset.10”
From Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report (2019) · cites this paper as [10]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [2]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [2]
38 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Self-citationGoate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Self-citationApolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationDiagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Self-citationStrittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363
Self-citationThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citation
Research works printed but not linked: 2
- Cornoni-Huntley, J., Blazer, D.G., Service, C. & Farmer, M.E. in Established population for epidemiologic studies of the elderly. Volume II (eds Cornoni-Huntley, J. et al.) 1–7 (NIH publication 90–495, Bethesda, 1990).
- Rothman, K.J. Modern Epidemiology. 38–39, 76 (Little, Brown & Company, Boston, 1986).
Cited by
Items 201–300 of 1,029
Plasma biomarkers for mild cognitive impairment and Alzheimer's disease
Song, F., Poljak, A., Smythe, G. A., & Sachdev, P. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.05.003 · Cited by 173
“Longitudinal studies have shown the ApoE ɛ2 allele to be a protective factor for AD (Corder et al., 1994) and cognitive decline (Blacker et al., 2007; Wilson et al., 2002).”
BackgroundAPOE genotype and MRI markers of cerebrovascular disease: Systematic review and meta-analysis
Schilling, S., DeStefano, A. L., Sachdev, P. S., Choi, S. H., Mather, K. A., DeCarli, C. D., Wen, W., Høgh, P., Raz, N., Au, R., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31829bfda4 · Cited by 172
“While the association ofAPOE e4with an increased burden of CVD could be partly contributing to the relationship between APOE e4 and AD, APOE e2 was associated with MRI markers of CVD in the opposite direction compared to AD.”
ResultInfluentialRole of apolipoprotein E in neurodegenerative diseases
Van Giau, V., Bagyinszky, E., An, S. S., & Kim, S. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s84266 · Cited by 171
“Conversely, there was evidence suggesting that the APOE ε2 allele may be protective against AD or associated with a marked reduction in AD risk.(54,55) AD risk in the APOE ε2/ε2 or ε2/ε3 carriers was lower than in those carrying ε3/ε3.”
BackgroundKoch, W., Ehrenhaft, A., Griesser, K., Pfeufer, A., Müller, J., Schömig, A., & Kastrati, A. (2002) · Clinical Chemistry and Laboratory Medicine · doi:10.1515/cclm.2002.197 · Cited by 171
“Contrasting the pathogenic potential of ε4, the ε2 allele was reported to protect from atherosclerosis (15, 16), myocardial infarction (18), and Alzheimer’s disease (19, 20).”
BackgroundHooijmans, C. R., Van der Zee, C. E. E. M., Dederen, P. J., Brouwer, K. M., Reijmer, Y. D., van Groen, T., Broersen, L. M., Lütjohann, D., Heerschap, A., & Kiliaan, A. J. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.12.002 · Cited by 171
Therapeutic approaches targeting Apolipoprotein E function in Alzheimer’s disease
Williams, T., Borchelt, D. R., & Chakrabarty, P. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-0358-9 · Cited by 171
Aβ-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease
Huang, Y. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.04.004 · Cited by 170
Neuroplasticity in Alzheimer's disease
Teter, B., & Ashford, J. W. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10441 · Cited by 170
“Are genetic factors in AD progeroid genes? For example, ApoE4 is associated with decreased longevity compared to E2 (Corder et al., 1994).”
BackgroundHorsburgh, K., McCarron, M. O., White, F., & Nicoll, J. A. R. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00097-x · Cited by 170
AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease
Rosenberg, J. B., Kaplitt, M. G., De, B. P., Chen, A., Flagiello, T., Salami, C., Pey, E., Zhao, L., Ricart Arbona, R. J., Monette, S., et al. (2018) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.231 · Cited by 176
“In humans, the APOE4 and APOE2 alleles are codominant; E2/E4 heterozygotes have only double the risk of E3/E3 homozygotes, and equivalent expression of E2 almost cancels out the deleterious effect of the E4 allele.(6,14,15) There is strong experimental evidence that the APOE isoforms are major determinants of the amou…”
BackgroundNathan, B. P., Jiang, Y., Wong, G. K., Shen, F., Brewer, G. J., & Struble, R. G. (2002) · Brain Research · doi:10.1016/s0006-8993(01)03367-4 · Cited by 169
Martínez-Morillo, E., Hansson, O., Atagi, Y., Bu, G., Minthon, L., Diamandis, E. P., & Nielsen, H. M. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1266-2 · Cited by 168
“APOE ε4 is the major risk factor of late-onset Alzheimer’s disease (AD) with an average frequency of 49 % [48] versus 14 % in general population [9], whereas APOE ε2 has a protective effect [4].”
BackgroundPrevention of Alzheimer's disease and dementia. Major findings from the Kungsholmen Project
Fratiglioni, L., Winblad, B., & von Strauss, E. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.05.059 · Cited by 168
“APOE ε4 allele is associated with an increased risk of developing AD [20] as well as with an earlier disease onset [21].”
BackgroundBrain Microvascular Changes in Alzheimer's Disease and Other Dementiasa
BUÉE, L., HOF, P. R., & DELACOURTE, A. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb48457.x · Cited by 165
Mutter, J., Curth, A., Naumann, J., Deth, R., & Walach, H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100705 · Cited by 162
Seshadri, S. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540350068018 · Cited by 163
Hu, J., Liu, C.-C., Chen, X.-F., Zhang, Y.-W., Xu, H., & Bu, G. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0001-3 · Cited by 161
“gene is the strongest genetic risk factor for late-onset AD (LOAD), whereas the ε2 allele is protective [2-6].”
BackgroundLoss of the neuroprotective factor sphingosine 1-phosphate early in Alzheimer’s disease pathogenesis
Couttas, T. A., Kain, N., Daniels, B., Lim, X. Y., Shepherd, C., Kril, J., Pickford, R., Li, H., Garner, B., & Don, A. S. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-9 · Cited by 161
“AD [13].”
Schiepers, O. J. G., Harris, S. E., Gow, A. J., Pattie, A., Brett, C. E., Starr, J. M., & Deary, I. J. (2012) · Molecular Psychiatry · doi:10.1038/mp.2010.137 · Cited by 159
The apolipoprotein E varepsilon2 allele and decline in episodic memory
Wilson, R. S. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.6.672 · Cited by 161
APOE and cholesterol homeostasis in Alzheimer's disease
Leduc, V., Jasmin-Bélanger, S., & Poirier, J. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.07.008 · Cited by 160
More than cholesterol transporters: lipoprotein receptors in CNS function and neurodegeneration
Lane-Donovan, C., Philips, G. T., & Herz, J. (2014) · Neuron · doi:10.1016/j.neuron.2014.08.005 · Cited by 158
“Meanwhile, the ApoE2 isoform is protective against AD relative to ApoE3 and ApoE4 (Corder et al., 1994).”
Carlson, G. A., Borchelt, D. R., Dake, A., Turner, S., Danielson, V., Coffin, J. D., Eckman, C., Meiners, J., Nilsen, S. P., Younkin, S. G., et al. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.11.1951 · Cited by 158
Neurofibrillary tangle-predominant dementia: comparison with classical Alzheimer disease
Jellinger, K. A., & Attems, J. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0156-7 · Cited by 167
“The paucity of amyloid deposition and the absence of 4 usually associated with increased A deposition in both AD and CAA [6, 16, 18, 63, 65, 73, 90] raise the possibility that 2 and 3 might be protective, but since 2 decreases the risk of AD [ 17 ] but increases the risk of CAA [39, 70], while only 3 may have a protec…”
Gefen, T., Peterson, M., Papastefan, S. T., Martersteck, A., Whitney, K., Rademaker, A., Bigio, E. H., Weintraub, S., Rogalski, E., Mesulam, M.-M., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2998-14.2015 · Cited by 156
“The most extensively documented genetic risk factor for dementia due to Alzheimer neuropathology is the ApoE 4 allele (Corder et al., 1993; Corder et al., 1994), which is also associated with patterns of cortical atrophy (Geroldi et al.”
BackgroundChalmers, K., Wilcock, G. K., & Love, S. (2003) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2003.00457.x · Cited by 156
Presenilins and Alzheimer’s disease: biological functions and pathogenic mechanisms
Czech, C., Tremp, G., & Pradier, L. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00033-7 · Cited by 158
TheFEAR: a rapid screening instrument for generalized anxiety in elderly primary care attenders
Krasucki, C., Ryan, P., Ertan, T., Howard, R., Lindesay, J., & Mann, A. (1999) · International Journal of Geriatric Psychiatry · doi:10.1002/(sici)1099-1166(199901)14:1<60::aid-gps893>3.0.co;2-g · Cited by 54
Hooijmans, C. R., Rutters, F., Dederen, P. J., Gambarota, G., Veltien, A., van Groen, T., Broersen, L. M., Lütjohann, D., Heerschap, A., Tanila, H., et al. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.06.007 · Cited by 154
“Identification of the cholesterol transporter apolipoprotein E4 as a major genetic risk factor for hypercholesterolemia, vascular dementia and sporadic AD (Corder et al., 1994; Poirier et al., 1993; Strittmatter et al., 1993), also reinforces the relationship between cholesterol and AD.”
BackgroundThe Genetics of the Amyloidoses
Buxbaum, J. N., & Tagoe, C. E. (2000) · Annual Review of Medicine · doi:10.1146/annurev.med.51.1.543 · Cited by 173
Alzheimer’s disease, cerebrovascular disease, and the β-amyloid cascade
Honjo, K., Black, S. E., & Verhoeff, N. P. L. G. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100015547 · Cited by 152
The Important Interface Between Apolipoprotein E and Neuroinflammation in Alzheimer’s Disease
Kloske, C. M., & Wilcock, D. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00754 · Cited by 152
“The ApoE2 allele has been shown to be protective for AD compared to the ApoE3 allele, being present in about 5% of all AD cases and about 9% in the general population (19).”
BackgroundIncreased CSF cortisol in AD is a function of APOE genotype
Peskind, E. R., Wilkinson, C. W., Petrie, E. C., Schellenberg, G. D., & Raskind, M. A. (2001) · Neurology · doi:10.1212/wnl.56.8.1094 · Cited by 152
Apolipoprotein E Genetic Variation and Alzheimer’s Disease
Rubinsztein, D. C., & Easton, D. F. (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017120 · Cited by 151
Rogaeva, E. (1998) · JAMA · doi:10.1001/jama.280.7.614 · Cited by 150
A pooled case-control study of the apolipoprotein E (APOE) gene in age-related maculopathy
Schmidt, S., Klaver, C. C. W., Saunders, A. M., Postel, E. A., De La Paz, M. A., Agarwal, A., Small, K. W., Udar, N., Ong, J. M., Chalukya, M. V., et al. (2002) · Ophthalmic Genetics · doi:10.1076/opge.23.4.209.13883 · Cited by 149
Self-citationFrisoni, G. B., Govoni, S., Geroldi, C., Bianchetti, A., Calabresi, L., Franceschini, G., & Trabucchi, M. (1995) · Annals of Neurology · doi:10.1002/ana.410370509 · Cited by 149
Chromosome Missegregation and Trisomy 21 Mosaicism in Alzheimer's Disease
Geller, L. N., & Potter, H. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0236 · Cited by 149
Molecular genetics of Alzheimer's disease
Cruts, M., & vanBroeckhoven, C. (1998) · Annals of Medicine · doi:10.3109/07853899809002605 · Cited by 148
Reduced functional brain activity response in cognitively intact apolipoprotein E ε4 carriers
Lind, J., Persson, J., Ingvar, M., Larsson, A., Cruts, M., Van Broeckhoven, C., Adolfsson, R., Bäckman, L., Nilsson, L.-G., Petersson, K. M., et al. (2006) · Brain · doi:10.1093/brain/awl054 · Cited by 148
“…response was observed in the parietal cortex such that homozygous carriers of the risk allele exhibited greater reduction than heterozy- gous carriers, which strengthens the association between reduced activity in this brain region and risk for Alzheimer’s disease (Corder et al., 1993, 1994).”
BackgroundApolipoprotein E and Alzheimer Disease: An Update on Genetic and Functional Analyses
Saunders, A. M. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.9.751 · Cited by 148
“The APOE4 allele is associated with an earlier age at onset of the common form of AD (13); the APOE2 allele confers a decreased risk and older age at onset (14).”
Self-citationLöwe, L. C., Gaser, C., Franke, K., & Initiative, A. D. N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157514 · Cited by 166
“Examining age specific effects also has the potential to test, whether the correlation of APOE ε4 with the AD risk and gross brain morphology diminishes in very old age [2, 21, 84].”
BackgroundResultInfluentialLower Cognitive Performance in Normal Older Adult Male Twins Carrying the Apolipoprotein E 4 Allele
Reed, T., Carmelli, D., Swan, G. E., Breitner, J. C. S., Welsh, K. A., Jarvik, G. P., Deeb, S., & Auwerx, J. (1994) · Archives of Neurology · doi:10.1001/archneur.1994.00540240033012 · Cited by 145
Skoog, I., Hesse, C., Aevarsson, O., Landahl, S., Wahlstrom, J., Fredman, P., & Blennow, K. (1998) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.1.37 · Cited by 145
“Although we did not find an association between the genotype of apoE and the incidence of all dementias, there were associations with the incidence of different types of dementia. The apoE e2 allele was associated with a higher incidence of multi-infarct dementia and a tendency towards a lower incidence of Alzheimer’s…”
ResultApolipoprotein E controls the risk and age at onset of Parkinson disease
Li, Y. J., Hauser, M. A., Scott, W. K., Martin, E. R., Booze, M. W., Qin, X. J., Walter, J. W., Nance, M. A., Hubble, J. P., Koller, W. C., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000128089.53030.ac · Cited by 144
“APOE-34 157 (222) 18 (32) 139 (190) 107 (146) 50 (76) 14 (15)”
Self-citationBales, K. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00143-3 · Cited by 143
Holtzman, D. M. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:2:147 · Cited by 143
“…to this study, numerous studies have confirmed that the ε4 allele is an AD risk factor (particularly in the age range of 60–80) and that the ε2 allele appears to be protective against AD (Corder et al., 1993; Mayeux et al., 1993; Corder et al., 1994; Poirer, 1994; Strittmatter and Roses, 1996).”
BackgroundAlzheimer's Disease Pathogenesis: Role of Aging
HARMAN, D. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1354.065 · Cited by 142
Apolipoprotein E Phenotype and Cognitive Decline in a Prospective Study of Elderly Community Women
Yaffe, K., Cauley, J., Sands, L., & Browner, W. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550210044011 · Cited by 143
Hampel, H. J., Lista, S., Teipel, S. J., Garaci, F., Nisticò, R., Blennow, K., Zetterberg, H., Bertram, L., Duyckaerts, C. J., Bakardjian, H., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.11.009 · Cited by 160
Alzheimer’s disease: Insights from epidemiology
McDowell, I. (2001) · Aging Clinical and Experimental Research · doi:10.1007/bf03351474 · Cited by 195
Velocardiofacial Syndrome in Childhood-Onset Schizophrenia
USISKIN, S. I., Nicolson, R., Krasnewich, D. M., Yan, W., Lenane, M., Wudarsky, M., Hamburger, S. D., & Rapoport, J. L. (1999) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199912000-00015 · Cited by 156
Amyloid-β in Alzheimer Disease: The Null versus the Alternate Hypotheses
Lee, H., Zhu, X., Castellani, R. J., Nunomura, A., Perry, G. L., & Smith, M. A. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.114009 · Cited by 157
“Interestingly, apolipoprotein 2 inhibits fibril formation and is protective against the development of AD (Corder et al., 1994).”
BackgroundRönnlund, M., Sundström, A., Adolfsson, R., & Nilsson, L. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.11.006 · Cited by 137
“The removal of participants with an APOE 24 combination [29] (n 5 33) did not alter the results.”
ResultTwenty years of Alzheimer’s disease‐causing mutations
Goate, A., & Hardy, J. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07575.x · Cited by 137
Genetic Aspects of Alzheimer Disease
Williamson, J., Goldman, J., & Marder, K. S. (2009) · The Neurologist · doi:10.1097/nrl.0b013e318187e76b · Cited by 135
“The 2 allele is associated with the lowest LOAD risk, whereas the 4 allele is associated with an increased risk for LOAD and a younger age of onset of dementia in a dose-dependent manner.(10,11) The increased risk for LOAD has also been demonstrated in different ethnic populations including African-Americans and Carib…”
BackgroundApolipoprotein-E (Apoe) ε4 and cognitive decline over the adult life course
Rawle, M. J., Davis, D., Bendayan, R., Wong, A., Kuh, D., & Richards, M. (2018) · Translational Psychiatry · doi:10.1038/s41398-017-0064-8 · Cited by 137
Plomin, R., & Crabbe, J. (2000) · Psychological Bulletin · doi:10.1037/0033-2909.126.6.806 · Cited by 136
Perioperative Stroke in Infants Undergoing Open Heart Operations for Congenital Heart Disease
Chen, J., Zimmerman, R. A., Jarvik, G. P., Nord, A. S., Clancy, R. R., Wernovsky, G., Montenegro, L. M., Hartman, D. M., Nicolson, S. C., Spray, T. L., et al. (2009) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2009.03.030 · Cited by 135
Qin, S., Colin, C., Hinners, I., Gervais, A., Cheret, C., & Mallat, M. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5186-05.2006 · Cited by 135
“Whereas the E2 allele is associated with a decreased risk of AD, the E4 allele increases the risk (Corder et al., 1993, 1994).”
BackgroundPhysical activity and the maintenance of cognitive function
Rockwood, K., & Middleton, L. (2007) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.01.003 · Cited by 135
Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions
Seto, M., Weiner, R. L., Dumitrescu, L., & Hohman, T. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00452-5 · Cited by 135
“In contrast, APOE-ε2 is considered to be a protective factor against AD [43, 73].”
BackgroundApolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex.
Bickeböller, H., Campion, D., Brice, A., Amouyel, P., Hannequin, D., Didierjean, O., Penet, C., Martin, C., Pérez‐Tur, J., Michon, A., et al. (1997) · Europe PMC (PubMed Central) · Cited by 155
TANG, M., MAESTRE, G., TSAI, W., LIU, X., FENG, L., CHUNG, W., CHUN, M., SCHOFIELD, P., STERN, Y., TYCKO, B., et al. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb32593.x · Cited by 134
McKeith, I. G., Burn, D. J., Ballard, C. G., Collerton, D., Jaros, E., Morris, C. M., McLaren, A., Perry, E. K., Perry, R., Piggott, M. A., et al. (2003) · Seminars in Clinical Neuropsychiatry · doi:10.1053/scnp.2003.50006 · Cited by 149
Ji, Z.-S., Pitas, R. E., & Mahley, R. W. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13452 · Cited by 134
Secretase Targets for Alzheimer's Disease: Identification and Therapeutic Potential
Wolfe, M. S. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0004897 · Cited by 133
Genetics of Alzheimer’s Disease
Vilatela, M. E. A., López, M., & Yescas, P. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.10.017 · Cited by 165
Pathophysiology of Alzheimer's Disease
Imbimbo, B. P., Lombard, J., & Pomara, N. (2005) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2005.09.009 · Cited by 154
“[32] Corder EH, Saunders AM, Risch NJ, et al.”
BackgroundInfluentialvan Duijn, C. M., de Knijff, P., Wehnert, A., De Voecht, J., Bronzova, J. B., Havekes, L. M., Hofman, A., & van Broeckhoven, C. (1995) · Annals of Neurology · doi:10.1002/ana.410370510 · Cited by 130
Jackson, M., Al‐Chalabi, A., Enayat, Z. E., Chioza, B., Leigh, P. N., & Morrison, K. E. (1997) · Annals of Neurology · doi:10.1002/ana.410420518 · Cited by 130
Liao, F., Hori, Y., Hudry, E., Bauer, A. Q., Jiang, H., Mahan, T. E., Lefton, K. B., Zhang, T. J., Dearborn, J. T., Kim, J., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0646-14.2014 · Cited by 147
“The 4 allele of apolipoprotein E (apoE) has been established as the strongest genetic risk factor for late-onset AD (Corder et al., 1993; Strittmatter et al., 1993a; Strittmatter et al., 1993b; Corder et al., 1994; Belinson and Michaelson, 2009).”
BackgroundThe apolipoprotein E gene, attention, and brain function.
Parasuraman, R., Greenwood, P. M., & Sunderland, T. (2002) · Neuropsychology · doi:10.1037//0894-4105.16.2.254 · Cited by 128
“In contrast, the 2 allele appears to confer a protective effect with regard to AD risk (Corder et al., 1994; Farrer et al., 1997; Lippa et al., 1997).”
Is APOE -ε4 a risk factor for cognitive impairment in normal aging?
Small, B. J., Graves, A. B., McEvoy, C. L., Crawford, F. C., Mullan, M., & Mortimer, J. A. (2000) · Neurology · doi:10.1212/wnl.54.11.2082 · Cited by 128
Bartzokis, G., Lu, P. H., Geschwind, D. H., Edwards, N., Mintz, J., & Cummings, J. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.1.63 · Cited by 128
Examination of the current top candidate genes for AD in a genome-wide association study
Feulner, T. M., Laws, S. M., Friedrich, P., Wagenpfeil, S., Wurst, S. H. R., Riehle, C., Kuhn, K. A., Krawczak, M., Schreiber, S., Nikolaus, S., et al. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.141 · Cited by 128
Burgess, B. L., McIsaac, S. A., Naus, K. E., Chan, J. Y., Tansley, G. H. K., Yang, J., Miao, F., Ross, C. J. D., van Eck, M., & Hayden, M. R. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.06.007 · Cited by 115
Harrington, C. R., Louwagie, J., Rossau, R., Vanmechelen, E., Perry, R. H., Perry, E. K., Xuereb, J. H., Roth, M., & Wischik, C. M. (1994) · PubMed · doi:10.25405/ncl.34087548 · Cited by 125
Clinical application of apolipoprotein E genotyping to Alzheimer's disease
Roses, A., Strittmatter, W., Pericak-Vance, M., Corder, E., Saunders, A., & Schmechel, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92960-2 · Cited by 125
Self-citationShafi, O. (2016) · BMC Neurology · doi:10.1186/s12883-016-0765-2 · Cited by 125
“Genotype APOE2 and E3 are associated with lowest risk of AD [46].”
BackgroundEpigenomics of Alzheimer's disease
Bennett, D. A., Yu, L., Yang, J., Srivastava, G. P., Aubin, C., & De Jager, P. L. (2015) · Translational Research · doi:10.1016/j.trsl.2014.05.006 · Cited by 123
ABCA7 and Pathogenic Pathways of Alzheimer’s Disease
Aikawa, T., Holm, M.-L., & Kanekiyo, T. (2018) · Brain Sciences · doi:10.3390/brainsci8020027 · Cited by 124
Healthy Aging and Dementia: Two Roads Diverging in Midlife?
Irwin, K., Sexton, C., Daniel, T., Lawlor, B., & Naci, L. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00275 · Cited by 124
“…the ε4 allele imposes a greater risk of developing AD compared to the ε3 allele, increasing in a dose dependent manner from 20 to 90% in homozygous carriers (Corder et al., 1993), whereas the ε2 allele has been suggested to provide a protective effect, lowering the risk of AD (Corder et al., 1994).”
BackgroundGenetic susceptibility to Alzheimer disease
Pericak‐Vance, M. A., & Haines, J. L. (1995) · Trends in Genetics · doi:10.1016/s0168-9525(00)89161-1 · Cited by 140
Self-citationApoE isoform affects LTP in human targeted replacement mice
Trommer, B. L., Shah, C., Yun, S. H., Gamkrelidze, G., Pasternak, E. S., Ye, G. L., Sotak, M., Sullivan, P. M., Pasternak, J. F., & LaDu, M. J. (2004) · NeuroReport · doi:10.1097/00001756-200412030-00020 · Cited by 124
“Our finding that LTP in apoE2-TR was comparable with apoE4-TR (and significantly less than apoE3-TR andWT) was surprising given the neuroprotective effects of E2 in both clinical [3,4] and experimental [20] settings.”
BackgroundResultOsorio, R. S., Ayappa, I., Mantua, J., Gumb, T., Varga, A., Mooney, A. M., Burschtin, O. E., Taxin, Z., During, E., Spector, N., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.12.030 · Cited by 124
“, 1993), while the ApoE2 allele is protective (Corder et al., 1994) although it may predispose individuals to cerebral amyloid angiopathy and be a risk factor for brain hemorrhage and/or white matter disease (Lemmens R et al.”
BackgroundTempleton, A. R. (1995) · Genetics · doi:10.1093/genetics/140.1.403 · Cited by 124
“The cladistic analysis confirms the inference of CHARTIER-HARLIN et al. ( 1994) that the € 2 allele is associated with a low incidence of A D , an association found in other studies as well for late-onset cases (CORDER et al. 1994; WEST et al. 1994).”
ResultPankratz, N., Byder, L., Halter, C., Rudolph, A., Shults, C. W., Conneally, P. M., Foroud, T., & Nichols, W. C. (2006) · Movement Disorders · doi:10.1002/mds.20663 · Cited by 123
Self-citationWilhelmus, M. M. M., de Waal, R. M. W., & Verbeek, M. M. (2007) · Molecular Neurobiology · doi:10.1007/s12035-007-0029-7 · Cited by 122
“The ɛ4 allele of ApoE is the major genetic risk factor for AD, whereas the ɛ2 allele appears to be protective against AD [21–24].”
BackgroundThe amyloid cascade and Alzheimer's disease therapeutics: theory versus observation
Castellani, R. J., Plascencia‐Villa, G., & Perry, G. L. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0231-z · Cited by 139
Corder, E. H., Lannfelt, L., Viitanen, M., Corder, L. S., Manton, K. G., Winblad, B., & Basun, H. (1996) · Archives of Neurology · doi:10.1001/archneur.1996.00550050048022 · Cited by 122
Self-citationBuée‐Scherrer, V., Buée, L., Hof, P. R., Leveugle, B., Mourton-Gilles, C., Loerzel, A. J., Perl, D. P., & Delacourte, A. (1995) · Europe PMC (PubMed Central) · Cited by 122
Leveraging preclinical models for the development of Alzheimer disease therapeutics
Scearce-Levie, K. A., Sanchez, P. E., & Lewcock, J. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0065-9 · Cited by 128
Hua, X., Hibar, D. P., Ching, C. R. K., Boyle, C. P., Rajagopalan, P., Gutman, B. A., Leow, A. D., Toga, A. W., Jack, C. R., Harvey, D., et al. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2012.10.086 · Cited by 120
“The ApoE ε2 variant is rare and has been shown to be protective against Alzheimer's disease (Corder et al., 1994).”
Genetic studies in Alzheimer's disease with an NACP/α‐synuclein polymorphism
Xia, Y., de Silva, H. A. R., Rosi, B. L., Yamaoka, L. H., Rimmler, J. B., Pericak‐Vance, M. A., Roses, A. D., Chen, X., Masliah, E., DeTeresa, R. M., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410400212 · Cited by 133
Self-citationHypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change
Soldan, A., Pettigrew, C., Cai, Q., Wang, M.-C., Moghekar, A. R., O’Brien, R. J., Selnes, O. A., Albert, M. S., & for the BIOCARD Research Team (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0194 · Cited by 118
Apolipoprotein E Deficiency Worsens Outcome From Global Cerebral Ischemia in the Mouse
Sheng, H., Laskowitz, D. T., Mackensen, G. B., Kudo, M., Pearlstein, R. D., & Warner, D. S. (1999) · Stroke · doi:10.1161/01.str.30.5.1118 · Cited by 118
Donohoe, G. G., Salomäki, A., Lehtimäki, T., Pulkki, K., & Kairisto, V. (1999) · Clinical Chemistry · doi:10.1093/clinchem/45.1.143 · Cited by 118
“Conversely, the inheritance of one or more e2 alleles confers protection against AD (5) and is associated with lower lipid concentrations (6).”
Heparin-Protein-Wechselwirkungen
Capila, I., & Linhardt, R. J. (2002) · Angewandte Chemie · doi:10.1002/1521-3757(20020201)114:3<457::aid-ange457>3.0.co;2-a · Cited by 118
Mueller, S. G., Schuff, N., Raptentsetsang, S., Elman, J., & Weiner, M. W. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.04.174 · Cited by 116
“A protective effect for Apo e2 has been reported (Corder et al., 1994).”
Background
Metadata
- Authors
- Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A.
- Affiliations
- Duke University (US)
- Yale University (US)
- Massachusetts General Hospital (US)
- Indiana University School of Medicine (US)
- University of California, Los Angeles (US)
- Venue
- Nature Genetics
- Published
- 1994-06
- Volume
- 7
- Issue
- 2
- Pages
- 180-184
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2090271811
- Cited by
- 1,920
- References
- 41
- Citations by year
- 2026: 45 · 2025: 77 · 2024: 78 · 2023: 59 · 2022: 66 · 2021: 76 · 2020: 76 · 2019: 58 · 2018: 62 · 2017: 58 · 2016: 75 · 2015: 55 · 2014: 63 · 2013: 68 · 2012: 66
- FWCI
- 54.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (NIA AG05128, U24AG021886)
- National Institute of Neurological Disorders and Stroke (P01NS026630, NINDS NS26630, NINDS NS531153)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, late-onset Alzheimer's disease, familial Alzheimer's disease, gene dosage, protective effect, sporadic Alzheimer's disease, genetic risk factors, APOE genotype
- MeSH terms
- Aged, Alleles, Alzheimer Disease, Apolipoproteins E, Female, Gene Frequency, Genotype, Humans, Male, Middle Aged, Risk Factors, Odds Ratio, Age of Onset
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.